Management for Distressed Companies (either public or private) We can bring in a team with world class expertise in turning around distressed bioscience companies, supported as needed by strong external professionals.  To see if this makes sense for your situation, you may contact us for a quick consultation 24/7, and we charge no fees for a first assessment meeting to discuss the situation with your team.    Once retained, we will provide expert analysis and will propose . . . and inplement . . . solutions for whatever challenges you are facing:  cash depletion, technology failures, equivocal clinical trial results, bad corporate deals, tired investors, litigation, low employee morale, etc.  Our experienced executives can expand the grim options your Board may now be considering, and provide your company with the on-site guidance that it needs to succeed.    Among the options we may propose are inserting either a full time or part time turnaround or workout CEO, an executive chairman or vice-chairman to support your incumbent CEO, or a complete C-level team to either augment or replace current management.  Once inside the company, we have a strong track record of aggressively and successfully solving the many types of problems that may be plaguing your company.  Almost always, we are able to significantly reduce expenditures through the recommendation and implementation of specific expense cuts.  Such cuts may not be possible with your current management team in place.  We will bring new faces to the table—crucial in the event that corporate deals need renegotiating, debts need restructuring, or clinical trials need to be redesigned or repeated.  In our experience, tired or reticent investors or corporate partners are more likely to reinvest in your company and its programs once they see these improvements unfold, and employees almost always rise to the occasion as well.   Our track record indicates that we will very likely discover new opportunities for your company that had been overlooked by previous management.  Plus, there is a good chance that we may increase the value of your company during a short turnaround, after which a well timed and orderly sale may yield far better returns than currently expected.  Your company deserves every chance to succeed before your Board faces the grim alternatives of a “fire sale” to a larger company (if that is even possible in today’s market), or liquidation, possibly via bankruptcy.    If it turns out that liquidation is the only viable option, then we can help you do it quickly, efficiently, with the best possible outcome for all stakeholders.     ----   "I recruited [Reed] as a "turn around CEO"  for a small privately owned UK development stage [bioscience] business of which I was Chairman at the time. Following his appointment Reed consolidated operations from seven facilities down to two, reduced world wide headcount from 100 down to 67, refocused the management team and reduced cash burn by 35% while increasing revenues by 11%. I can therefore recommend Reed to anyone seeking such expert input for development stage companies." -- Sir Charles Masefield, President, BAE Systems and Chairman, Helvetica (Swiss Bank)   “I was an increasingly frustrated member of the Board of a publicly held biotech company.  I feared that a number of critical business problems were threatening the ability of that company to complete its mission of commercializing a very important new drug.  As a result, the Board and I brought in Reed and his team.  They took immediate action, slashing the burn rate from $22 million down to $8 million, spinning off underutilized assets, renegotiating IP licenses with a major university and a large foreign pharmaceutical company, restructuring a corporate deal with a major multinational drug company, and bringing in a very attractive new partnership from yet another corporate partner.  Through all of this, employee morale remained high, the drug made it successfully through both the clinical trials and the FDA approval process, and the company was sold at a price of more than seven times its previous market value.  That drug is now a very important tool in the ongoing war on cancer.  I would strongly recommend Reed and his team to any Board facing such daunting business challenges.” -- John R. Silber, Ph.D., President Emeritus and University Professor, Boston University   "I was a Director at [a bioscience company] and Reed was CEO. In the face of failure of the primary technology he licensed a new technology platform from [a major university] and on that basis sold the company to [a large biotech firm]. Reed's actions avoided significant losses by the investors."  -- John Fried, Ph.D., former Vice Chairman & President of the Research Division, Syntex Pharmaceuticals